- Medicine - Feb 23 Angela Merkel discusses global antibiotic challenge with Imperial researcher
- Medicine - Feb 23 MOU with Monash University
- Medicine - Feb 23 Sugar’s ‘tipping point’ link to Alzheimer’s disease revealed
- Life Sciences - Feb 23 UCL part of new £100 million Rosalind Franklin Institute
- Medicine - Feb 23 Type 2 diabetes prevented in 80 percent of at-risk patients with repurposed drug
- Medicine - Feb 23 Eating more fruits and vegetables may prevent millions of premature deaths
- Medicine - Feb 22 Opinion: How years of IMF prescriptions have hurt West African health systems
- Medicine - Feb 22 Education does not protect against cognitive decline
- Careers - Feb 22 NICE consults on guideline to improve response to child abuse
- Medicine - Feb 21 Partnership for patient care marks BioWales 2017
- Life Sciences - Feb 21 Cocaine addiction leads to build-up of iron in brain
- Environment - Feb 21 Legal marijuana sales creating escalating damage to the environment
Liverpool spin-out gets further funding boost for bedside sepsis test
A University of Liverpool spin-out company, Sepsis Limited has secured further funding support to test a point of care diagnostic tool for the early detection of sepsis.
The Small Business Research Initiative for Healthcare ( SBRI Healthcare ), led by the Academic Health Science Networks ( AHSNs ), has awarded the company £100,000 for the first phase of testing a working prototype of a hand held device that will be used at the patient bedside for rapid diagnosis and treatment of sepsis.
The award is part of an NHS England initiative aimed at helping healthcare organisations to improve their flow of patients.
Often referred to as blood poisoning, sepsis is the major cause of death worldwide. In the UK, approximately 100,000 people are admitted to hospital with sepsis and around 37,000 people will die as a result of the condition.
Sepsis Limited, which was spun out in 2010, is founded on the ground breaking research of blood specialist Professor Cheng-Hock Toh from the University’s Institute of Infection and Global Health.
The company’s hand-held device can detect abnormal blood chemistry due to bacterial sepsis within minutes of sampling and before standard physiological sepsis is diagnosed. It has been designed to frequently monitor progression of symptoms with a view to improve and measure the appropriate use of antibiotics and collectively meet objectives of the Department of Health’s UK Five Year Antimicrobial Resistance Strategy 2013-2018 .
Professor Toh, who also provides direct patient care at the Royal Liverpool University Hospital, said: ‘This new funding is an important step in helping us to translate our research into a bedside test that can quickly diagnose life-threatening sepsis, improve antibiotic usage, and ultimately save lives.’
Last job offers
- Medicine/Pharmacology - 24.2
Senior Lecturer/ Reader (Associate Professor)
- Medicine/Pharmacology - 22.2
Professorship of Clinical Microbiology
- Medicine/Pharmacology - 18.2
Associate Professor in Pharmacy
- Medicine/Pharmacology - 17.2
Professor of Ambulatory Care- 12875
- Medicine/Pharmacology - 13.2
Senior Lecturer (Honorary Consultant) in Stroke Medicine
- Medicine/Pharmacology - 13.2
PA to Alborada Professor (Head of Department) (Maternity Cover)
- Medicine/Pharmacology - 6.2
Clinical Associate Professor in Equine Surgery
- Medicine/Pharmacology - 3.2
Lecturer / Associate Professor in Exercise and/or Health Psychology